AICentralResources
AI Tool Comparison

Comparing as AI Medical Research & Clinical Decision Support
BenevolentAI vs Nabla

BenevolentAI

BenevolentAI

VS
Nabla

Nabla

Verdict by Category

Detailed category analysis is not available for this comparison.
View BenevolentAI View Nabla

Detailed Comparison

Feature
BenevolentAI
Nabla
Pricing
CustomBenevolentAI operates through enterprise pharma collaboration agreements and platform licensing — there is no self-serve access or published pricing. Revenue models include: discovery collaborations with pharma companies (AstraZeneca, Merck) structured as multi-year agreements with upfront fees and milestones; licensing of its knowledge exploration tools as standalone software to pharma R&D organizations; and advancing its own clinical pipeline to inflection points for licensing or co-development. Total funding raised is approximately $1.9B, with the company listed on Euronext Amsterdam (AMS: BAI). Contact BenevolentAI through benevolent.com for partnership and platform licensing inquiries.
FreemiumNabla does not publish exact pricing on its official website; the primary calls-to-action are a free trial (via app.nabla.com) and "Talk to our team" for enterprise sales. Third-party sources consistently report a free tier with usage limits, with paid individual/clinician plans starting around $119/month per provider and higher tiers reported near $239/month per provider. Larger health-system deployments — Nabla's core market, spanning 130+ organizations — are sold via custom enterprise contracts with volume-based pricing, with independent estimates placing typical enterprise rates in the $150-$400/month per provider range depending on scale, EHR integration depth, and features. Exact costs require a sales conversation with Nabla.
Categories
AI Healthcare ToolsAI Research & Education Tools
AI Healthcare ToolsAI Productivity ToolsAI Developer APIs & Platforms
Summary
Clinical-stage AI drug discovery with integrated wet labs and AstraZeneca and Merck collaborations
Ambient AI that turns patient visits into clinical notes, dictation, and coding — right inside the EHR
BenevolentAI

BenevolentAI Pros & Cons

Pros

  • Fully integrated AI + wet lab model — unique among AI drug discovery platforms
  • AstraZeneca and Merck partnerships validate the platform's target identification quality
  • In-house wet labs in Cambridge close the loop between AI prediction and biology
  • Euronext Amsterdam listed (AMS: BAI) — $1.9B raised, publicly accountable
  • Phase 1 clinical data for BEN-8744 (ulcerative colitis) represents real clinical progress
  • Multiple disease areas covered: oncology, rare disease, CNS, fibrosis, and immunology
  • Knowledge exploration tools can be licensed separately from drug pipeline

Cons

  • Listed on Euronext Amsterdam (AMS: BAI) — less accessible to US retail investors
  • Clinical pipeline still in early stages — no approved drugs yet
  • Smaller than competitors like Recursion in terms of funding and team size
  • Revenue dependent on collaboration milestones — lumpy and uncertain
  • Wet-lab operations add cost complexity vs. pure software drug discovery peers
Nabla

Nabla Pros & Cons

Pros

  • Fast note generation, roughly five seconds, that closely mirrors real clinical documentation in independent tests
  • Deep native integration with Epic and other major EHRs rather than copy-paste workflows
  • Broad specialty and language coverage suited to large, diverse health systems
  • Strong compliance posture (HIPAA, SOC 2 Type 2, ISO 27001, GDPR) with configurable data retention
  • Backed by peer-reviewed evidence, including a NEJM AI randomized trial showing documentation-time reductions
  • Combines documentation, dictation, and coding in one platform instead of separate point tools

Cons

  • Pricing isn't published; individuals and smaller practices must go through a sales conversation or rely on third-party estimates to budget
  • Primarily built for hospitals and health systems, so solo clinicians and small practices may find it less tailored than SMB-focused scribes
  • Relies on ambient recording, so encounters where a patient or clinician can't or won't be recorded aren't well supported
  • Some independent reviews note limited customization and quality drop-off on complex, multi-problem visits
  • Mobile app store ratings are mixed and based on a relatively small number of reviews compared to the platform's overall clinician base